

Marcello Maugeri-Saccà (MD, PhD)

Present affiliation

1. Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy
2. Clinical Trial Center, Biostatistics and Bioinformatics Division, IRCCS Regina Elena National Cancer Institute, Rome, Italy

Research Interest

Oncogenomics, Immunotherapy and Precision Oncology.

Current Position

Group Leader

Academic History

2012: PhD (International PhD in Stem Cells)
Italian National Institute of Health (ISS), Rome

2008: Medical Oncologist
Medical Oncology School, Faculty of Medicine and Surgery, Messina University, Italy

2004: MD (honors)
Faculty of Medicine and Surgery, Messina University, Italy

Professional Licenses and Certifications

2008: Medical Oncology Certification

2005: License to practice Medicine

Funding and Awards

2017: Young Researcher Grant, Italian Ministry of Health (MoH)
Role: Principal Investigator
Period: 2017-2022
Amount: € 405.900

2019: My First AIRC Grant (MFAG), Italian Association for Cancer Research (AIRC)
Role: Principal Investigator
Period: 2020-2024
Amount: € 489.900

Reviewer Assignment (selection)

Annals of Oncology, BMC Medicine, Cancer Discovery, Cell Death & Differentiation, Cell Death & Disease, European Respiratory Journal, Journal for ImmunoTherapy of Cancer, Journal of Thoracic Oncology, NPJ Precision Oncology Oncogene, Oncogenesis.

List of publications (selection) in Peer-Reviewed Journals (first/last/corresponding author)

- Scalera S et al. KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy. *J Thorac Oncol.* 2021 (Cover article)
- Goeman F et al. Multicohort and cross-platform validation of a prognostic Wnt signature in colorectal cancer. *Clin Transl Med.* 2020
- Marinelli D et al. KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden. *Ann Oncol.* 2020
- Mazzotta M et al. Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes. *J Immunother Cancer.* 2020
- Goeman F et al. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma. *J Thorac Oncol.* 2019 (Cover article)
- Di Benedetto A et al. Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting. *Ther Adv Med Oncol* 2019
- Buglioni S et al. The clinical significance of PD-L1 in advanced gastric cancer is dependent on ARID1A mutations and ATM expression. *Oncoimmunology* 2018
- Pallocca M et al. Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer. *J Transl Med.* 2018
- De Nicola F et al. Deep sequencing and pathway-focused analysis revealed multigene oncodriver signatures predicting survival outcomes in advanced colorectal cancer. *Oncogenesis* 2018
- Mancini R et al. Metabolic features of cancer stem cells: the emerging role of lipid metabolism. *Oncogene.* 2018
- Melucci E et al. Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. *J Transl Med.* 2018

- Maugeri-Saccà M and De Maria R. The Hippo pathway in normal development and cancer. *Pharmacol Ther.* 2018
- Di Benedetto A et al. Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression. *Sci Rep.* 2017
- Ercolani C et al. Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapy. *Cancer Biol Ther.* 2017
- Ronchetti L et al. DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. *Int J Cancer.* 2017
- Barba M et al. Body mass index modifies the relationship between γ -H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer. *BMC Cancer.* 2017
- Di Benedetto A et al. Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast Cancer. *J Cell Physiol.* 2017
- Di Benedetto A et al. HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes. *Sci Rep.* 2016
- Maugeri-Saccà M et al. Presurgical window of opportunity trial design as a platform for testing anticancer drugs: pros, cons and a focus on breast cancer. *Crit Rev Oncol Hematol.* 2016
- Buglioni S et al. Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment. *Oncoimmunology.* 2016
- Di Benedetto A et al. The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer. *Oncotarget.* 2016
- Vici P et al. Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy. *J Exp Clin Cancer Res.* 2016
- Vici P et al. DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis. *PLoS One.* 2016
- Maugeri-Saccà M and De Maria R. Hippo pathway and breast cancer stem cells. *Crit Rev Oncol Hematol.* 2016
- Vici P et al. Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis. *Oncotarget.* 2015

- Di Lauro L et al. Androgen receptor and antiandrogen therapy in male breast cancer. *Cancer Lett.* 2015
- Maugeri-Saccà M et al. The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications. *Expert Rev Mol Med.* 2015
- Di Lauro L et al. Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis. *J Hematol Oncol.* 2015
- Di Lauro L et al. Efficacy of chemotherapy in metastatic male breast cancer patients: a retrospective study. *J Exp Clin Cancer Res.* 2015
- Maugeri-Saccà M et al. Cancer stem cells: are they responsible for treatment failure? *Future Oncol.* 2014
- Vici P et al. The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy. *Oncotarget.* 2014
- Di Lauro L et al. Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series. *Breast Cancer Res Treat.* 2014
- Maugeri-Saccà M et al. Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations. *Breast Cancer Res Treat.* 2014
- Maugeri-Saccà M et al. FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort. *J Exp Clin Cancer Res.* 2013
- Di Lauro L et al. Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer. *Gastric Cancer.* 2014
- Maugeri-Sacca M et al. Approaching the increasing complexity of non-small cell lung cancer taxonomy. *Curr Pharm Des.* 2014
- Di Lauro L et al. Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. *Breast Cancer Res Treat.* 2013
- Maugeri-Sacca M et al. Functional role of microRNAs in prostate cancer and therapeutic opportunities. *Crit Rev Oncog.* 2013
- Maugeri-Saccà M et al. Biological and clinical implications of cancer stem cells in primary brain tumors. *Front Oncol.* 2013

- Maugeri-Saccà M et al. Checkpoint kinase 1 inhibitors for potentiating systemic anticancer therapy. *Cancer Treat Rev.* 2013
- Maugeri-Saccà M et al. DNA damage repair pathways in cancer stem cells. *Mol Cancer Ther.* 2012
- Maugeri-Saccà M et al. MicroRNAs and prostate cancer: from preclinical research to translational oncology. *Cancer J.* 2012
- Maugeri-Saccà M, et al. Cancer stem cells and chemosensitivity. *Clin Cancer Res.* 2011
- Maugeri-Saccà M et al. Therapeutic targeting of cancer stem cells. *Front Oncol.* 2011

List of publications (selection) in Peer-Reviewed Journals (Contributing Author)

- Manic G et al. Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51. *Cell Death Differ.* 2021
- Pisanu ME et al. Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma. *J Exp Clin Cancer Res.* 2018
- Manic G et al. CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells. *Gut.* 2018
- Bartucci M et al. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. *Oncogene.* 2015
- Coppola V et al. BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial-mesenchymal transition. *Oncogene.* 2013
- Bartucci M et al. Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. *Cell Death Differ.* 2012
- Musumeci M et al. Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. *Oncogene.* 2011